PL3590542T3 - Peptydy znakowane radionuklidem emitującym pozytony do obrazowania upar metodą pet u ludzi - Google Patents

Peptydy znakowane radionuklidem emitującym pozytony do obrazowania upar metodą pet u ludzi

Info

Publication number
PL3590542T3
PL3590542T3 PL19193807.5T PL19193807T PL3590542T3 PL 3590542 T3 PL3590542 T3 PL 3590542T3 PL 19193807 T PL19193807 T PL 19193807T PL 3590542 T3 PL3590542 T3 PL 3590542T3
Authority
PL
Poland
Prior art keywords
upar
humans
imaging
positron emitting
emitting radionuclide
Prior art date
Application number
PL19193807.5T
Other languages
English (en)
Inventor
Andreas Kjaer
Morten PERSSON
Jacob MADSEN
Original Assignee
Curasight A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curasight A/S filed Critical Curasight A/S
Publication of PL3590542T3 publication Critical patent/PL3590542T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL19193807.5T 2012-12-03 2013-11-29 Peptydy znakowane radionuklidem emitującym pozytony do obrazowania upar metodą pet u ludzi PL3590542T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA201270751 2012-12-03

Publications (1)

Publication Number Publication Date
PL3590542T3 true PL3590542T3 (pl) 2024-05-13

Family

ID=50882823

Family Applications (2)

Application Number Title Priority Date Filing Date
PL19193807.5T PL3590542T3 (pl) 2012-12-03 2013-11-29 Peptydy znakowane radionuklidem emitującym pozytony do obrazowania upar metodą pet u ludzi
PL13860317T PL2928505T3 (pl) 2012-12-03 2013-11-29 Peptydy znakowane radionuklidem emitującym pozyton do obrazowania pet upar u ludzi

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL13860317T PL2928505T3 (pl) 2012-12-03 2013-11-29 Peptydy znakowane radionuklidem emitującym pozyton do obrazowania pet upar u ludzi

Country Status (8)

Country Link
US (4) US9884131B2 (pl)
EP (2) EP3590542B1 (pl)
CA (3) CA3106713C (pl)
DK (1) DK2928505T3 (pl)
ES (2) ES2972124T3 (pl)
HU (2) HUE046326T2 (pl)
PL (2) PL3590542T3 (pl)
WO (1) WO2014086364A1 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015532636A (ja) * 2012-05-08 2015-11-12 リグスホスピタレト 部位特異的ｕＰＡＲ標的化のための１７７−Ｌｕ標識ペプチド
ES2972124T3 (es) * 2012-12-03 2024-06-11 Curasight As Péptidos marcados con un radionúclido que emite positrones para obtención de imágenes de PET del uPAR humana
CN104725473B (zh) * 2014-09-11 2018-03-20 厦门大学附属第一医院 一种[18F]AlF标记的PET多肽探针及其制备方法
DK3193945T3 (da) * 2014-09-17 2020-11-16 Fluoguide As Upar-målrettende peptid til anvendelse ved peroperativ optisk billeddannelse af invasiv cancer
CA2969067A1 (en) 2014-11-25 2016-06-02 Bristol-Myers Squibb Company Novel pd-l1 binding polypeptides for imaging
CN107207379B (zh) 2014-11-25 2021-08-10 百时美施贵宝公司 用于生物制品的18f-放射性标记的方法和组合物
US10994033B2 (en) 2016-06-01 2021-05-04 Bristol-Myers Squibb Company Imaging methods using 18F-radiolabeled biologics
JP7016323B2 (ja) 2016-06-01 2022-02-21 ブリストル－マイヤーズ スクイブ カンパニー Ｐｄ－ｌ１結合ポリペプチドを用いるｐｅｔ造影
WO2019227490A1 (en) 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and methods for imaging
EP3818085A4 (en) 2018-06-01 2022-03-09 Tayu Huaxia Biotech Medical Group Co., Ltd. COMPOSITIONS AND THEIR USES FOR THE TREATMENT OF DISEASES OR DISORDERS
CN109285142B (zh) * 2018-08-07 2023-01-06 广州智能装备研究院有限公司 一种头颈部肿瘤检测方法、装置及计算机可读存储介质
CN113795511B (zh) 2019-01-23 2024-07-23 大有华夏生物医药集团有限公司 抗pd-l1双抗体及其用途
CA3239551A1 (en) 2021-11-30 2023-06-08 Curasight Aps Urokinase-type plasminogen activator receptor (upar)-pet/ct in head and neck squamous cell carcinomas (hnsccs)
EP4197561A1 (en) 2021-12-15 2023-06-21 Curasight A/S Urokinase-type plasminogen activator receptor (upar)-pet/ct in neuroendocrine neoplams
EP4735055A1 (en) 2023-06-27 2026-05-06 Curasight A/S Urokinase-type plasminogen activator receptor (upar)-pet/ct in brain tumours
EP4610269A1 (en) 2024-02-29 2025-09-03 3B Pharmaceuticals GmbH Urokinase plasminogen activator surface receptor (upar) ligands for diagnostic or therapeutic use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69535019T2 (de) 1994-03-11 2007-01-04 Wilson Greatbatch, Ltd. Elektromagnetische pumpe mit geringem vermögen
US6277818B1 (en) 1998-10-29 2001-08-21 Angstrom Pharmaceuticals, Inc. Cyclic peptide ligands that target urokinase plasminogen activator receptor
US5942492A (en) 1996-11-12 1999-08-24 Angstrom Pharmaceuticals, Inc. Cyclic peptides that bind to urokinase-type plasminogen activator receptor
AR020101A1 (es) 1998-07-01 2002-04-10 Cancerforskingsfonden Af 1989 Un antagonista peptido del receptor de uroquinasa humana, composicion farmaceutica que lo contiene, su uso para la manufactura de un medicamento y metodopara seleccionar un antagonista peptido adecuado.
US6896870B1 (en) * 1999-10-01 2005-05-24 Angstrom Pharmaceuticals, Inc. Diagnostic probes and therapeutics targeting uPA and uPAR
JP2003528035A (ja) 1999-10-01 2003-09-24 アングストロム ファーマシューティカルズ， インコーポレイテッド ｕＰＡおよびｕＰＡＲを標的化する診断プロ−ブおよび治療薬
EP1796733A2 (en) 2004-09-29 2007-06-20 GE Healthcare AS Urokinase plasminogen activator receptor targeted contrast agents
EP2056886A2 (en) * 2006-08-28 2009-05-13 GE Healthcare Limited 68ga-labeled peptide-based radiopharmaceuticals
EP2750717B1 (en) * 2011-08-31 2019-03-27 Somscan ApS Pet tracer for imaging of neuroendocrine tumors
CN102600489A (zh) 2012-02-24 2012-07-25 南方医科大学南方医院 含iRGD序列的多肽放射性药物
JP2015532636A (ja) * 2012-05-08 2015-11-12 リグスホスピタレト 部位特異的ｕＰＡＲ標的化のための１７７−Ｌｕ標識ペプチド
ES2972124T3 (es) * 2012-12-03 2024-06-11 Curasight As Péptidos marcados con un radionúclido que emite positrones para obtención de imágenes de PET del uPAR humana
DK3193945T3 (da) * 2014-09-17 2020-11-16 Fluoguide As Upar-målrettende peptid til anvendelse ved peroperativ optisk billeddannelse af invasiv cancer

Also Published As

Publication number Publication date
US20180193495A1 (en) 2018-07-12
CA3106713A1 (en) 2014-06-12
ES2972124T3 (es) 2024-06-11
EP3590542A1 (en) 2020-01-08
US11311637B2 (en) 2022-04-26
PL2928505T3 (pl) 2020-02-28
EP2928505B1 (en) 2019-08-28
CA3106713C (en) 2024-01-09
CA2903261A1 (en) 2014-06-12
CA2903261C (en) 2021-03-09
CA3221851A1 (en) 2014-06-12
EP3590542C0 (en) 2024-01-03
EP2928505A4 (en) 2016-08-24
US20160263260A1 (en) 2016-09-15
ES2755804T3 (es) 2020-04-23
US20220202966A1 (en) 2022-06-30
HUE046326T2 (hu) 2020-03-30
WO2014086364A1 (en) 2014-06-12
EP3590542B1 (en) 2024-01-03
US20200268914A1 (en) 2020-08-27
EP2928505A1 (en) 2015-10-14
HUE066607T2 (hu) 2024-08-28
US9884131B2 (en) 2018-02-06
DK2928505T3 (da) 2019-11-25
US12409240B2 (en) 2025-09-09

Similar Documents

Publication Publication Date Title
PL3590542T3 (pl) Peptydy znakowane radionuklidem emitującym pozytony do obrazowania upar metodą pet u ludzi
IL261259B (en) Compounds for positron emission tomography
EP2779432A4 (en) linear conveyor
PL3041507T3 (pl) Kwasy nukleinowe kodujące ludzkie przeciwciała przeciwko sialyl-lewis a
PL2863942T3 (pl) Cząstki sprzężone z peptydem
EP2816649A4 (en) CONVEYOR AND SUPPORT PROCESS
IL246344B (en) Ct system and method therefor
HUE043273T2 (hu) Fúziós fehérje
EP2849115A4 (en) METHOD FOR DECODING A TWO-DIMENSIONAL MATRIX CODE
PL2970589T3 (pl) Utwardzalne promieniowaniem politytioetery ze związkiem opartym na alkinie
PT3560937T (pt) Métodos de preparação de agentes de imagem por tep direcionados para amep marcado no 18f'' e seus métodos de diagnóstico
EP2970611A4 (en) THERMOPLASTIC COMPOSITE
ITRM20130667A1 (it) Impianto di alimentzione di caburante.
DK2782754T3 (da) Svejsbare oblater til PET.
PL3429233T3 (pl) Dekoder matrycowy z panoramowaniem parami o stałej mocy
EP3062783A4 (en) Imaging histone deacetylases with a radiotracer using positron emission tomography
FR2986233B1 (fr) Peptide bifonctionnel
DK3087076T3 (da) Imidazopyrazinonderivater
SG11201505378YA (en) Spectral-segmentation computation in radiation detectors
DK3065756T3 (da) Opbevaringsstabiliseret lyophiliseret tripeptidformuleringer
BR112015005911A2 (pt) vetores e métodos para melhorar a expressão de proteínas recombinantes em plantas.
FI9797U1 (fi) Paineenkorotusyksikkö
GB2510647A8 (en) In-mould labelling
GB201205778D0 (en) Positron emission detection and imaging
TWM475152U (en) Composite pet cage